[Neuroleptic adverse effects with emphasis on weight gain].
Hebebrand
Johannes
J
D000293:Adolescent; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001569:Benzodiazepines / Q000009:adverse effects / Q000627:therapeutic use; D001921:Brain / Q000187:drug effects; D009202:Cardiomyopathies / Q000139:chemically induced; D002648:Child; D003024:Clozapine / Q000009:adverse effects / Q000627:therapeutic use; D004409:Dyskinesia, Drug-Induced / Q000175:diagnosis; D004734:Energy Metabolism / Q000187:drug effects / Q000235:genetics; D005247:Feeding Behavior / Q000187:drug effects*; D005260:Female; D015870:Gene Expression / Q000187:drug effects; D056726:Genetic Association Studies; D006801:Humans; D008297:Male; D009205:Myocarditis / Q000139:chemically induced; D000077152:Olanzapine; D010493:Pericarditis / Q000139:chemically induced; D018967:Risperidone / Q000009:adverse effects / Q000627:therapeutic use; D005879:Tourette Syndrome / Q000188:drug therapy; D018433:Twin Studies as Topic; D015430:Weight Gain / Q000187:drug effects* / Q000235:genetics
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D003024:Clozapine; D018967:Risperidone; D000077152:Olanzapine
Neuroleptikanebenwirkungen mit Schwerpunkt Gewichtszunahme.